Ask AI
ProCE Banner Activity

Managing Patients With HER2+ Breast Cancer and Brain Metastasis: Slides

Slideset

Download these expert-selected slides on optimal treatment of patients with HER2-positive breast cancer with brain metastases.

Released: February 02, 2021

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Artios, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Bicycle, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb/SystImmune, Celcuity, Circle, Cullinan Oncology, Daiichi Sankyo, Denali, Eisai, Genentech/Roche, Gilead, Jazz, Johnson & Johnson/Ambrx, Launch, Lilly, Menarini/Stemline, Merck, Mersana, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen.